source
- #ASCO26: Lilly's plenaries; Incyte's frontline data in lymphomaTwo plenaries related to Lilly: Researchers detailed findings from an investigator-sponsored trial using Lilly’s CDK4/6 inhibitor Verzenio in a rare cancer called dedifferentiated liposarcoma, show…
- Revolution Medicines' pancreatic cancer trial shows striking positive resultsAt the American Society of Clinical Oncology meeting, Revolution Medicines presented data from its pivotal pancreatic cancer trial that impressed many observers. Oncologist Brian Wolpin described…